Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticoid Injection for PIP Joint Sprains
NCT02916940Phase 2Completed
- Sponsor
- CHU Brugmann
- Start
- Nov 2016
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of betamethasone dipropionate + betamethasone sodium phosphate in Proximal Interphalangeal Joint Sprain (2 arms), sponsored by CHU Brugmann. Primary endpoints: Flexion/Extension Deficit at 30 days, Laxity in Hyperextension at 30 days and 2 more. Started Nov 2016; status: completed.
02
Drugs
betamethasone dipropionate + betamethasone sodium phosphate
03
Conditions
Proximal Interphalangeal Joint Sprain
Beyond the preview
Go deeper on NCT02916940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916940.